Exact Sciences/Oncotype DX

Gold

Information

The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to help optimize cancer treatment decisions. In prostate cancer, the Oncotype DX Genomic Prostate Score® test predicts disease aggressiveness and further clarifies the current and future risk of the cancer prior to treatment intervention, and the Oncotype DX AR-V7 Nucleus Detect® test helps determine which patients with metastatic castration-resistant prostate cancer (mCRPC) are resistant to androgen receptor (AR)-targeted therapies.

Interest
Oncology - Prostate/Testis/Penis/Urethra

Social media

Contact details

Products & Services

Videos

Documents & Links